spacer
home > ebr > autumn 2017 > editors letter
PUBLICATIONS
European Biopharmaceutical Review

Editors Letter

Since our last edition of EBR went to print, there have been significant innovations in new medicines, including those for heart disease, with the anti-inflammatory canakinumab (anti-interleukin-1 beta/ ACZ885) described in the media as the ‘biggest breakthrough in cardiovascular medicine since statins...’ (1). Additionally, the milestone approval of Kymrhia (tisagenlecleucel) in the US, the first chimerical antigen receptor (CAR) T-cell therapy for blood cancers, heralds “a new frontier” of medicine, according to Scott Gottlieb at the FDA (2). These are exciting new next-generation biopharmaceuticals, biological and advanced therapy medicinal products (ATMPs), the latter being the ultimate in personalised medicine, generated from the patient’s own lymphocytes.

A key component of the successful and, arguably, much more established drug development pathways for small molecules that require first pass liver metabolism is an understanding of their metabolism and kinetic properties, from both a safety and efficacy perspective. Dr Richard Weaver FRSC of XenoGesis Ltd highlights the importance of early expertise in drug metabolism and pharmacokinetics and absorption distribution metabolism elimination properties for development pathways. Meanwhile, Optibrium Ltd’s Matthew Segall looks at the role of mathematical and computational modelling of cytochrome P450 interactions.

For any therapy employing human tissue systems at the preclinical phase of development – such as the 3D organoid introduced by QGel’s Dr Colin Sanctuary or the tailored, precision medicine tissue systems the Glasgow-based Aridhia, ReproCELL Europe and Stratified Medicine Scotland team are continuing to pioneer – can better predict drug response outcomes in terms of safety and efficacy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Deborah O’Neil, Chief Executive and Scientific Officer, NovaBiotics Ltd
spacer
Dr Deborah O’Neil
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Prometic Bioseparations are very pleased to introduce their new purpose built ecommerce platform (Webshop)!

Their goal was to build a platform that is easy to navigate, informative and one that makes their products and services easily accessible to researchers and laboratories worldwide. They also wanted to make ordering as quick and easy as possible to meet the needs of the rapidly progressive industry. They have reflected these requirements with an ecommerce store in order to supply high quality products to customers from academia to big pharma.
More info >>

White Papers

Nanoparticle Tracking Analysis. A Review of Applications and Usage in the Analysis of Exosomes and Microvesicles

NanoSight

The study of exosomes and other cell-derived microvesicles is an area of rapidly growing importance and the subject of intense interest and research. The previous lack of suitable methods for their detection, analysis, enumeration and phenotyping is proving to be a significant limitation in these studies. This mini-review shows the degree to which the technique of Nanoparticle Tracking Analysis (NTA) is helping to address these problems.
More info >>

 
Industry Events

Cell Line Development and Engineering

23-25 April 2018, RAI, Amsterdam

Cell Line Development & Engineering 2018 event will be held 23-25 April 2018 in the RAI Amsterdam – joining the largest Bioprocessing event in Europe – BPI Europe.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement